Head-To-Head Analysis: Gelteq (NASDAQ:GELS) and Corcept Therapeutics (NASDAQ:CORT)

Corcept Therapeutics (NASDAQ:CORT) and Gelteq (NASDAQ:GELS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Insider & Institutional Ownership

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Corcept Therapeutics and Gelteq, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0	0	5	0	3.00
Gelteq	0	0	0	0	0.00

Corcept Therapeutics presently has a consensus target price of $99.75, indicating a potential upside of 78.09%. Given Corcept Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Gelteq.

Earnings & Valuation

This table compares Corcept Therapeutics and Gelteq”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$675.04 million	8.75	$106.14 million	$1.24	45.17
Gelteq	N/A	N/A	N/A	N/A	N/A

Corcept Therapeutics has higher revenue and earnings than Gelteq.

Profitability

This table compares Corcept Therapeutics and Gelteq’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	22.35%	24.54%	20.24%
Gelteq	N/A	N/A	N/A

Summary

Corcept Therapeutics beats Gelteq on 9 of the 9 factors compared between the two stocks.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

About Gelteq

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.